A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
H. Lundbeck A/S
Age
55–91
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have participated in the 331-14-213 study.
Participants must have an identified caregiver who has contact, at a minimum of 2 hours per day, 4 days per week to describe the participant's symptoms and can observe participant behavior.
You may not be if
Participants with a substantial protocol violation during the course of their participation in the double-blind trial 331-14-213.
